Tier 2 — strong

Dietary supplementation with the anti-tumour promoter quercetin: its effects on matrix metalloproteinase gene regulation

D M Morrow, P E Fitzsimmons, M Chopra, H McGlynn
Mutation research 2001 480-481:269

Bibliography

PubMed
PMID 11506819
DOI
10.1016/s0027-5107(01)00184-1
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignPlacebo-controlled short-term human biomarker study
ModelHuman intervention research
SampleHealthy men aged 33–64; sample size not stated in the indexed abstract
InterventionQuercetin 30 mg/day in a blackcurrant drink or placebo
Duration14 days
EndpointsExposure and pharmacokinetics; Protein activity, binding or signaling

What the study showed, in plain terms

Published in 2001, this source examined evidence reviews and human mechanisms. Design: Placebo-controlled short-term human biomarker study. Sample/model: Healthy men aged 33–64; sample size not stated in the indexed abstract. The exposure or intervention was Quercetin 30 mg/day in a blackcurrant drink or placebo. Follow-up or treatment period: 14 days.

TIMP-1 expression and concentration decreased; MMP-2 and TIMP-2 did not change.

These molecular markers have complex biological roles. The study did not test cancer incidence, tumor regression, or established clinical prevention.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • TIMP-1 expression and concentration decreased; MMP-2 and TIMP-2 did not change.
  • The recorded outcome domains were Exposure and pharmacokinetics; Protein activity, binding or signaling.
  • The result applies to the tested exposure: Quercetin 30 mg/day in a blackcurrant drink or placebo; 14 days.

What this study can and cannot tell us

  • These molecular markers have complex biological roles. The study did not test cancer incidence, tumor regression, or established clinical prevention.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo
Inka Boomgaarden et al. · The British journal of nutrition · 2010
Tier 2
Effect of dietary quercetin on oxidative DNA damage in healthy human subjects
E R Beatty et al. · The British journal of nutrition · 2000

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology